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Dear Editor,
We read with interest the paper by Kaplowitz et al. pub-
lished in the June issue of the journal [1]. The authors are to be
commended for their effort in this topic. We would like to
make the following remarks on their article:
Firstly, we would like to bring to their attention a publica-
tion by our group that addressed the safety and efficacy of
needling combined with 5-fluorouracil (5-FU) injections for
failing Ahmed glaucoma implants [2]. As Kaplowitz et al.
have not discussed or cited our paper, we believe the readers
of the journal would benefit by considering our results here. In
our prospective single-group observational study, 36 primary
open-angle glaucoma patients with failing Ahmed valves
underwent totally 67 needling procedures with concurrent 5-
FU injection. The patients were examined 1 week following
the needling and then at months 1, 3, and 6 with subsequent
visits every 6months for a minimum period of 2 years. Table 1
presents a summary of our data [2] and data by Kaplowitz
et al. for the 5-FU group [1]. Although a direct comparison
of the data shown in Table 1 cannot be performed, it seems
that needling with 5-FU offers better long-term IOP control
than 5-FU injections alone. Of note, our patients were younger
than the patients of Kaplowitz et al. [2] and the valve model
we used (S2) theoretically induces more fibrosis than the FP-7
model used by Kaplowitz et al. [2]. It is also interesting that
almost half as many interventions were performed in our sam-
ple compared to the sample of Kaplowitz et al. (1.86 vs. 3.4).
A further comment on the study by Kaplowitz et al. [1] is
about their decision to use the Bpaired Student’s t test^ for the
comparison of IOP values between the control and treatment
groups. We would have expected that the unpaired, rather than
the paired t test would have been appropriate for the compar-
ison of data from different patients [3].
Table 1 Summary of data for the study group of the paper by
Kaplowitz et al. [1] and the patients analyzed by Quaranta et al. [2]
Kaplowitz et al.
(study group) [1]
Quaranta et al. [2]
Number of eyes 44 36
Mean number of
injections
3.4 1.86
Valve model FP-7 S2
Mean age of
participants (years)
63.7 58.3
Months since
implantation
4.6 (137 days) 20.1
Pre-needling IOP
(mmHg)
25.3 29.5
Success in
post-injection
months:
12/18/24/60
- / - / - / 77%
(defined as IOP
<21 mmHg
and >20% IOP
reduction without
reoperation)
75% / 75% /72.2%/ -
(defined as IOP
≤18 mmHg with
or without
medications)
IOP (mmHg) in
post-injection
months: 12/18/24
(number of
medications)
17.9 (2.5) / 18.1 (2.6)
/17.0 (2.6)
16.4 (2.2) /15.4 (2.0)
/ 15.4 (1.9)
IOP intraocular pressure
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Finally, in the paper by Kaplowitz et al. [1] the IOP differ-
ences between the 5-FU group and the control group during
the follow-up period do not always reach statistical signifi-
cance. Nonetheless, these differences are certainly clinically
relevant (e.g., 12.9 vs. 17.2 mmHg for the control and the
study groups, respectively, at the 60-month follow-up visit,
p = 0.23). We believe that IOP differences of this magnitude
(i.e., 4.3 mmHg for the 60-month visit) would surely be con-
sidered clinically important. Therefore, the authors’ statement
that B...the 5-FU-treated group did no worse than controls^ is
correct in a statistical sense, but not in a clinical sense. As
acknowledged by the authors, patient retention was low in
their study. It is quite probable that the lack of statistical sig-
nificance for such clinically important IOP differences is due
to the small number of patients remaining at follow-up. Due to
the small retention, the Kaplan–Meier survival analysis data
should also be interpreted with caution, especially for the last
follow-up visits.
We believe that our report [2] and the one by Kaplowitz
et al. [1] are contributions to the literature that may prove
useful for clinicians treating glaucoma patients with failing
Ahmed implants.
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